Voiding Dysfunction Among Older Adults With Non‐Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder
Neurourology and Urodynamics · 2026-04 · 45 (4) · 727-737
DOI: 10.1002/nau.70269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurourology and Urodynamics, online erschienen am 19.03.2026. Verfasst von Boris Gershman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Leonard and Lee Ann Samia Bladder Cancer Research Fund, Bladder Cancer Research Program Fund.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Introduction
Non‐muscle invasive bladder cancer (NMIBC) is a chronic disease with a lifelong treatment burden that may cause substantial urinary morbidity. Such quality‐of‐life changes remain understudied. We therefore evaluated the incidence and predictors of treatment for overactive bladder (OAB) among older adults following diagnosis of NMIBC. Materials and Methods We identified adults aged 66–89 years with newly diagnosed NMIBC from 2007 to 2017 in the linked SEER‐Medicare database. We examined the incidence of treatment initiation for OAB following initial transurethral resection of bladder tumor (TURBT) and evaluated associations with baseline characteristics using Cox regression.
Results
We identified 9,819 patients, of whom 68% had Ta disease, 29% had T1 disease, and 4% had CIS. Within the first 12 months of TURBT, 7% of patients received treatment for OAB, and this increased to 15% of patients at 5 years. In the first year, the most utilized therapies were anticholinergic medications (early 3.72%, late 2.74%) and beta‐3 agonists (early 0.11%, late 0.32%), while procedural OAB therapy utilization was rare (0.2%). On multivariable analysis, female gender (HR 1.26, 95% CI 1.11–1.42), congestive heart failure (HR 1.21, 95% CI 1.03–1.43), and T1 tumor stage (HR 1.27, 95% CI 1.12–1.44 vs. Ta) were independently associated with an increased risk of OAB treatment.
Conclusions
The incidence of OAB requiring treatment among patients with NMIBC is substantial, with approximately one in six patients receiving treatment by 5 years after diagnosis. Predictive clinicopathologic features for OAB treatment—including, sex, high‐risk tumor features, and repeat TURBT—may be useful for clinical counseling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Urology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Agustin Perez-Londono, Jamil Almohtasib, Sumedh Kaul, Aria F Olumi, Brian J Linder
Förderung
- Leonard and Lee Ann Samia Bladder Cancer Research Fund
- Bladder Cancer Research Program Fund
Zitieren
APA
Gershman, B., Perez-Londono, A., Almohtasib, J., Kaul, S., Fleishman, A., Boorjian, S. A., Olumi, A. F., & Linder, B. J. (2026). Voiding Dysfunction Among Older Adults With Non‐Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder. Neurourology and Urodynamics, 45(4), 727-737. https://doi.org/10.1002/nau.70269
Vancouver
Gershman B, Perez-Londono A, Almohtasib J, Kaul S, Fleishman A, Boorjian SA, et al. Voiding Dysfunction Among Older Adults With Non‐Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder. Neurourology and Urodynamics. 2026;45(4):727-737. doi:10.1002/nau.70269
BibTeX
@article{Gershman2026,
author = {Gershman, Boris and Perez-Londono, Agustin and Almohtasib, Jamil and Kaul, Sumedh and Fleishman, Aaron and Boorjian, Stephen A and Olumi, Aria F and Linder, Brian J},
title = {Voiding Dysfunction Among Older Adults With Non‐Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder},
journal = {Neurourology and Urodynamics},
year = {2026},
volume = {45},
number = {4},
pages = {727--737},
doi = {10.1002/nau.70269}
}
EUVIMED